Effect of clarithromycin on the pharmacokinetics of 2',3'- dideoxyinosine in patients who are seropositive for human immunodeficiency virus

Clinical Infectious Diseases

Volumn 22, Issue 4, 1996, Pages 716-718

  Gillum, J Gregory ^b   Bruzzese, Vivian L ^b   Israel, Debra S ^b   Kaplowitz, Lisa G ^b   Polk, Ron E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DIDANOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0029847979     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.4.716     Document Type: Article

References (10)

1. Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993;153:368-72.
2. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
3. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection: the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1994;330: 657-62.
4. Connolly KJ, Allan JD, Fitch H, et al. Phase I study of 2′,3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med 1991;91:471-8.
5. Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′,3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a Phase 1 trial. N Engl J Med 1990;322:1340-5.
6. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a Phase 1 trial. N Engl J Med 1990;322:1333-40.
7. Drusano GL, Yuen GJ, Morse G, et al. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob Agents Chemother 1992;36:1280-3.
8. 14C-didanosine in the beagle dog. Drug Metab Dispos Biol Fate Chem 1993;21:447-53.
9. Knupp CA, Shyu WC, Dolin R, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991;49:523-35.
10. Sifrim D, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and clarithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 1992;18:337-42.